Azenta Reports Steep Q2 Loss, $149M Goodwill Impairment, and Cuts Full-Year Guidance

summarizeSummary

Azenta, Inc. reported a significantly wider Q2 operating loss of $165.8 million, including a $149 million goodwill impairment charge, and substantially lowered its full-year fiscal 2026 revenue and Adjusted EBITDA margin guidance.

check_boxKey Events

• Steep Q2 Operating Loss

  Reported a GAAP operating loss of $165.8 million for Q2 FY2026, a significant increase from $18.2 million in the prior year, driven by execution gaps and a cautious demand environment.

• $149 Million Goodwill Impairment

  Recognized a substantial non-cash goodwill impairment charge of $149 million, primarily affecting the Multiomics and Sample Management Solutions reporting units, indicating a re-evaluation of asset values.

• Substantial Full-Year Guidance Cut

  Lowered fiscal 2026 revenue guidance to $603-$621 million (from prior 3-5% growth) and adjusted EBITDA margin expectations, reflecting reduced organic growth and profitability.

• Long-Range Plan Extended

  The timeline for achieving long-range plan targets has been extended by one year, from 2028 to 2029, in connection with the revised 2026 outlook.

auto_awesomeAnalysis

The Q2 FY2026 results for Azenta, Inc. are highly concerning, marked by a dramatic increase in operating loss to $165.8 million, primarily due to a $149 million non-cash goodwill impairment charge. This impairment suggests a significant re-evaluation of the value of acquired assets, particularly in the Multiomics and Sample Management Solutions segments, indicating underperformance relative to prior expectations. The company also significantly lowered its full-year fiscal 2026 guidance for both revenue and Adjusted EBITDA margin, signaling a deteriorating demand environment and execution challenges. Furthermore, the extension of the long-range plan timeline by a year underscores a slower path to achieving strategic targets. The failure to close the B Medical Systems divestiture due to the buyer's financing issues adds further uncertainty and risk. These combined factors present a very negative outlook for Azenta, impacting investor confidence and suggesting continued operational headwinds.